Related references
Note: Only part of the references are listed.On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Franck Morschhauser et al.
MOLECULAR CANCER THERAPEUTICS (2020)
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A. Burris et al.
LANCET ONCOLOGY (2018)
Duvelisib, an oral dual PI3K-, inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study
Ian W. Flinn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
Anas Younes et al.
HAEMATOLOGICA (2017)
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Martin Dreyling et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
Anas Younes et al.
HAEMATOLOGICA (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik et al.
ANNALS OF ONCOLOGY (2016)
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2016)
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]-quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
William J. Scott et al.
CHEMMEDCHEM (2016)
Idelalisib-associated Colitis Histologic Findings in 14 Patients
Anna-Sophie Weidner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
K. Balakrishnan et al.
LEUKEMIA (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard et al.
CLINICAL CANCER RESEARCH (2015)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phosphoinositide 3 '-Kinase Inhibition in Chronic Lymphocytic Leukemia
Matthew S. Davids et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Report From the Sixth International Workshop on Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Share Paper
